Navigation Links
FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia
Date:8/21/2008

RARITAN, N.J., Aug. 21 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced that the U.S. Food and Drug Administration (FDA) requires additional information before it will approve the company's New Drug Application (NDA) for DORIBAX(TM) (doripenem for injection) for the treatment of hospital-acquired pneumonia, also known as nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP).

In response to the J&JPRD application seeking approval for DORIBAX for the additional indication of the treatment of NP, including VAP, the FDA issued a Complete Response letter outlining the actions necessary to address outstanding issues.

J&JPRD is reviewing the agency's letter and will work to resolve any outstanding questions. The NDA for DORIBAX for the treatment of NP, including VAP, was submitted to the FDA in June 2007.

The NDA for DORIBAX for the treatment of NP, including VAP, was the subject of a July 16, 2008 U.S. Food and Drug Administration Anti-Infective Drugs Advisory Committee. Based on data presented from two large nosocomial pneumonia trials, the committee voted that 500 mg of DORIBAX at both the one-hour and four-hour infusion regimens were safe (8-5) and effective (7-6) in the treatment of NP, including VAP. The committee did not agree that the non-inferiority margin for the DORIBAX NP trials was appropriately justified, nor did it agree on the appropriate margin for NP trials in general. J&JPRD is confident in the NP data submitted and will work with the FDA to address the issues raised in the Complete Response letter.

DORIBAX is an intravenous (IV) antibiotic for hospital use, and belongs to a class of antibacterial drugs called carbapenems. Carbapenems are important antibiotics to treat serious -- and sometimes life-threatening -- infections caused by a broad range of bacteria, which are characterized as Gram-negative and Gram-positive, based on a classification
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
2. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
3. AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panels Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
4. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
5. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
6. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
7. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
8. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
9. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
10. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
11. Go Healthy Initiates Additional Clinical Tests on Cholesterade
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... CITY, Calif. , July 24, 2014   ... specialty pharmaceutical company focused on the development and commercialization ... breakthrough pain, today confirmed the PDUFA date for Zalviso ... learned that a rumor circulated online stating the Food ... July 24, 2014 there has been no notification to ...
(Date:7/24/2014)... , and MARSEILLE, France , ... , Exclusive global license from University of Tokyo enables ... sequencing (NGS) gene panels, for blood cancers  ... test, indicate favorable prognosis for patients with bone marrow ... potential for developing companion diagnostics to guide treatment with ...
(Date:7/24/2014)... Amgen (NASDAQ: AMGN ) today announced ... Tuesday, July 29, 2014, after the close of the U.S. ... call with the investment community at 2 p.m. PT. Participating ... Bradway , chairman and chief executive officer, and other members ... the conference call will be simultaneously broadcast over the Internet ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
(Date:7/25/2014)... July 25, 2014 Newyorktermlifeinsurance.org has ... life insurance plans and traditional policies. , The ... clients make between no medical exam life insurance plans ... types of life insurance plans to provide a simple ... life insurance plans can now be purchased online. Although ...
(Date:7/25/2014)... July 25, 2014 CarePoint Health is ... Edward Boylan, has joined our network, CarePoint Health Medical ... Hundreds of highly skilled and experienced physicians comprise CarePoint ... and practices in Hudson County, representing a wide range ... to provide the highest quality care to patients and ...
(Date:7/25/2014)... Rockville Centre, NY (PRWEB) July 25, 2014 ... national personal injury law firm with over 25 ... of harm stemming from dangerous prescription drugs, announces ... , to offer information to those who believe ... Xarelto. , The site offers valuable information ...
(Date:7/25/2014)... TX (PRWEB) July 25, 2014 ... Outlook to 2020” provides company shares and distribution ... and global corporate-level profiles of the key market ... to the Laryngoscopes market wherever available. , The ... market forecast models. Rsearcher uses epidemiology and capital ...
(Date:7/25/2014)... Although cervical cancers are declining in the United States ... are increasing, a new study indicates. HPV-related cancers ... and tonsils have increased over the past 35 years, ... Canadian researchers report. "The increases in the incidence ... anal cancer among younger women are disturbing, because there ...
Breaking Medicine News(10 mins):Health News:No Medical Exam Life Insurance and Traditional Plans - Newyorktermlifeinsurance.org Provides Quotes for All Types of Life Insurance 2Health News:Dr. Boylan Joins CarePoint Health Medical Group 2Health News:Rottenstein Law Group LLP Announces Launch of Xarelto Injury Website 2Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 2Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 3Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 4Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 5Health News:Anal, Throat Cancers on the Rise Among Young Adults, Study Finds 2
... In a study of 14 adults with histories of ... not appear// to have effects that indicate potential for ... report in the October issue of Archives of General ... to 15 percent of adults regularly experience chronic insomnia, ...
... the time, they are nothing but a cosmetic nuisance. ... dividing abnormally to form a deadly form of skin ... this year will be diagnosed with melanoma at some ... percent of all melanomas begin in a mole. They ...
... of Nutrition in its current issue (October) has published ... Cookies TM can not only lower cholesterol levels but ... This would substantially curtail the risk of cardiac disease. ... purposes taken from the common fleawort, proven to be ...
... Health and Clinical Excellence (Nice) has planned new guidelines ... (porous bones) are at higher risk of fractures. The ... fragile bones. ,Post menopausal women at any ... wants to execute guidelines according to which, only women ...
... World Action on Salt and Health has been launched today ... 2.5 million deaths a year.// ,194 medical experts in ... companies into reducing dietary salt intake to prevent high blood ... a World Health Organisation summit in Paris to discuss the ...
... research proposes that the drug used to treat wet age-related ... vision in some people. // ,Wet AMD is the ... can be regained to some extent in people with a ... drug Lucentis. ,The study was published in the ...
Cached Medicine News:Health News:New Sleep Medication not Effective for Treating Abuse or Cognitive Impairment 2Health News:New Sleep Medication not Effective for Treating Abuse or Cognitive Impairment 3Health News:Why Don’t All Moles Progress to Melanoma 2Health News:Why Don’t All Moles Progress to Melanoma 3Health News:Chocolate Chip Cookies to Keep Cholesterol at Bay 2Health News:Food Makers Pressurized to Reduce Salt 2Health News:Vision restoration with a drug for macular degeneration 2
The EK-H Series offer 10 selectable units of measure...
Digital Thermometer & High-Low Temp Alarm, -50C to +90C...
Thermometer for Round Water Bath...
... Digital Thermostat and Digital Display. , Exterior300 ... , Interiorwhite anodized aluminum with 300 ... refrigeration (134A). , Temperature range 0C ... doors. , Foamed-in-place polyurethane high density ...
Medicine Products: